Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synta Pharmaceuticals has reported interim results of ganetespib (STA-9090) form IIB/III Ganetespib Assessment in Lung cAncer with docetaXel (Galaxy) trial.
Subscribe to our email newsletter
Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which is required for the proper folding and activation of many cancer-promoting proteins.
The randomized trial is designed to compare the combination of ganetespib and docetaxel versus docetaxel alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) who have received one prior systemic therapy.
Preclinical experiments conducted on Ganetespib has shown its inhibition effect as a single agent and also in combination with other drugs in multiple tumor models.
In addition to NSCLC treatment, the company has conducted various clinical trails including the Chiara Phase 2 trial demonstrating ganetespib monotherapy in ALK+ NSCLC and the ENCHANT Phase 2 trial evaluating ganetespib as first-line treatment for HER2+ and triple-negative metastatic breast cancer.
The company is also evaluating ganetespib in its investigator-sponsored trials for the treatment of lung, breast, prostate, gastric, pancreatic, and colorectal, ocular melanoma, acute myeloid leukemia and multiple myeloma cancers.
The company said the interim results of Galaxy trial will be presented at the European Society of Medical Oncology Congress held in between 28 September to 2 October 2012 in Vienna, Austria.